Skip to search formSkip to main contentSkip to account menu

FOLFOX Regimen

Known as: CF/5-FU/L-OHP, FOLFOX, Fluorouracil/Leucovorin Calcium/Oxaliplatin 
An abbreviation for a chemotherapy combination used to treat colorectal cancer that is advanced or has come back. It is also being studied in the… 
National Institutes of Health

Related topics

Related topics

4 relations
FluorouracilFolfox protocolLeucovorin Calciumoxaliplatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.
3509Background: The molecular subtyping of colon cancers (CC) has been the subject of several recent publications, leading to an… 
Highly Cited
2012
Highly Cited
2012
Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I…
PurposeThe primary objective of this study is to evaluate the safety, tolerance, and pharmacokinetic profile of liver-directed… 
Highly Cited
2008
Highly Cited
2008
Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors
15545 Background: Inhibitors of the VEGF pathway have been shown to have activity in neuroendocrine tumors (NET). Oxaliplatin… 
2008
2008
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG…
4009 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of… 
Review
2008
Review
2008
Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Cetuximab is a recently approved monoclonal antibody that targets the epidermal growth factor receptor, a receptor tyrosine… 
2008
2008
Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
4022 Background: Resection of initially unresectable metastatic lesions in pts with mCRC who have responded to systemic therapy… 
2007
2007
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX)
Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi‐Aventis, Paris, France) combined with irinotecan (IROX) were examined in… 
Highly Cited
2006
Highly Cited
2006
Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?
BackgroundCombination chemotherapy using oxaliplatin, 5-fluorouracil and folinic acid (FOLFOX) is known to be effective in the… 
Review
2006
Review
2006
Role of panitumumab in the management of metastatic colorectal cancer.
Panitumumab (formerly known as ABX-EGF) is the first fully human monoclonal antibody directed against the epidermal growth factor… 
Highly Cited
2004
Highly Cited
2004
OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer.
3525 Background: FOLFOX4 has shown superiority over LV5FU2 and IFL in first line therapy. Limiting toxicities are neutropenia… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)